8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 29, 2015

ONCOMED PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-35993	38-3572512
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

800 Chesapeake Drive

Redwood City, California 94063

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 995-8200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD.

The Company will host a Research and Development (R&D) Day for its institutional investors and research analysts on Wednesday, April 29, 2015 from 8:00 a.m. to approximately 12:00 p.m. EDT in New York City. A webcast of the presentation will be accessible through a link in the Investor Relations section of the OncoMed website: http://www.oncomed.com. The webcast will also be recorded and available for replay and archived on the OncoMed website for approximately 60 days following the presentation. The full text of the press release announcing the above is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is located on the Company’s website at www.oncomed.com under “Investors – Press Releases.”

The information in Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 29, 2015	ONCOMED PHARMACEUTICALS, INC.
	By:	/s/ Sunil Patel
		Sunil Patel Chief Financial Officer, Senior Vice President, Corporate Development and Finance

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release

EX-99.1

Exhibit 99.1

For Immediate Release

OncoMed Pharmaceuticals to Webcast 2015 Research and Development Day on April 29, 2015

Redwood City, Calif., April 23, 2015 - OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and immuno-oncology pathways, will host a Research and Development (R&D) Day for its institutional investors and research analysts on Wednesday, April 29, 2015 from 8:00 a.m. to approximately 12:00 pm EDT in New York City.

Presentations from OncoMed’s management team are expected to focus on recently updated data from OncoMed’s most advanced clinical candidates; breakthrough discoveries related to OncoMed’s emerging immuno-oncology pipeline; and an overview of OncoMed’s approach to cancer biology and drug development, including the latest research related to ongoing predictive biomarker programs.

OncoMed’s 2015 R&D Day will also feature discussions with special guest speakers. Manuel Hidalgo, MD, PhD, Director of the Centro Integral Oncológico Clara Campal (CIOCC), START Madrid, will speak with Jakob Dupont, M.D., on pancreatic cancer and his experience as an investigator in the company’s demcizumab (anti-DLL4, OMP-21M18) clinical trials. Jorge DiMartino, MD, PhD, Vice President, Translational Development of Celgene Corporation will also be on hand to discuss Celgene’s multi-product collaboration with OncoMed.

OncoMed management team speakers will include:

• Paul Hastings, Chairman and Chief Executive Officer

• John Lewicki, PhD, Executive Vice President, Chief Scientific Officer

• Jakob Dupont, MD, Senior Vice President, Chief Medical Officer

• Austin Gurney, PhD, Senior Vice President, Molecular and Cellular Biology

• Tim Hoey, PhD, Senior Vice President, Cancer Biology

• Ann Kapoun, PhD, Vice President, Translational Medicine

OncoMed invites the public and media to listen to the presentations via a live webcast that can be accessed under the Investor Relations section of the company’s website (www.oncomed.com). Presentations are scheduled to begin at approximately 8:00 a.m. Eastern Daylight Time. A replay of the webcast will be archived on the OncoMed website for approximately 60 days following the presentation.

Qualified institutional investors and research analysts may register to attend the OncoMed 2015 R&D Day by contacting Michelle Corral, Senior Director, Investor Relations and Corporate Communications (michelle.corral@oncomed.com) or Shari Annes, Investor Relations Consultant (shari.annes@oncomed.com)

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has six anti-cancer product candidates in clinical development, the most advanced of which are in randomized Phase 2 clinical trials. Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28) each target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed recently filed an Investigational New Drug application for anti-RSPO3 (OMP-131R10), an antibody targeting a third key cancer stem cell signaling pathway called R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and immuno-oncology product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and

OncoMed Pharmaceuticals to Webcast 2015 Research and Development Day

Page 2 of 2

GlaxoSmithKline (GSK). Additional information can be found at the company’s website: www.oncomed.com.

# # #

Contact:
Media & Investors	Investors
OncoMed Pharmaceuticals	Shari Annes
Michelle Corral	Annes Associates
Senior Director, Investor Relations and Corporate Communications	shari.annes@oncomed.com (650) 888-0902
michelle.corral@oncomed.com
(650) 995-8373